cDNA of DOCK180 gene and DOCK180 protein

Abstract

The present invention provides a cDNA of DOCK180 gene, which has a nucleotide sequence of SEQ ID NO: 1 and of which translation product binds to the proto-oncogene product CRK, a recombinant vector containing this cDNA, a DOCK180 protein expressed from the EDNA which has a amino acid sequence of SEQ ID NO: 2, and an antibody to the DOCK180 protein. According to the present invention, It is possible to develop new diagnosing and therapeutic techniques using DOCK180 protein and antibody against the protein.

Description

BACKGROUND OF THE INVENTION

1. Field of the Invention

The present invention relates to a cDNA of DOCK180 protein, which binds to the proto-oncogene product CRK, a recombinant vector containing this cDNA, a DOCK180 protein expressed from the cDNA, and an antibody to the DOCK180 protein. The cDNA of the present invention, the DOCK180 protein, and the antibody are very useful for diagnosis of tumor cells and development of a cancerocidal method for suppressing tumor cells.

2. Description of Related Art

Recent progress of cellular biology and molecular biology is really remarkable. Active research efforts are being made on carcinogenesis on the genetic level, and such efforts have identified many oncogenes and antioncogenes associated with human. It is also known that various proteins are expressed from these genes.

For example, CRK protein, which is expressed from a proto-oncogene CRK, is one of the major proteins controlling proliferation of higher eukaryote, and is known to regulate proliferation of tumor cells in many malignant tumors.

It has now been revealed that this CRK protein functions through binding to DOCK180 protein. DOCK180 is therefore attracting attention as a diagnostic indicator of tumor cells and as a target for missile therapy using various antitumor agents.

However, because no information has been available about a gene encoding the DOCK180 protein, it has been impossible to effectively utilize this protein widely for diagnosis of cancerous diseases, clarification of carcinogenesis mechanism, or development or a new cancer therapy.

SUMMARY OF THE INVENTION

The present invention has an object to provide a cDNA of DOCK 180 gene and a genotic engineering material permitting easy manipulation of this cDNA and expression of the protein in a large scale.

The present invention has another object to provide a DOCK180 protein which is expressed from the above-mentioned cDNA, and an antibodies against this protein.

The present invention provides a cDNA of the DOCK180 gene, which has the nucleotide sequence defined in Sequence Listing by SEQ ID NO: 1.

Furthermore, the present invention provides a recombinant vector containing the cDNA of DOCK180 gene. More concretely, the present invention provides the plasmid pDOCK180 held by E. coli DOCK180 (FERM BP-5362).

The present invention further provides a DOCK180 protein having the amino acid sequence defined in Sequence Listing by SEQ ID NO: 2, and antibodies to DOCK180 protein prepared by using the DOCK180 protein as an antigen.

BRIEF DESCRIPTION OF THE DRAWING

FIG. 1 is a constitutional diagram of pDOCK180, which is a cloning vector of the present invention.

DETAILED DESCRIPTION OF THE INVENTION

The cDNA of the present invention can be isolated and purified from higher eukaryotes such as cells derived from human, mouse, and chicken by the application of, for example, the method of Sambrook et al.(Molecular Cloning, second edition, Cold Spring Harbor Laboratory, New York, 1989). More specifically, the cDNA can be obtained by purifying mRNA of DOCK180 protein gene from animal cell, and then synthesizing a cDNA chain from the mRNA by the use of reverse transcriptase. From among the thus synthesizable cDNAs of DOCK180 protein, the nucleotide sequence of cDNA derived from human cells and the amino acid sequence of the translation domain thereof are defined in Sequence Listing by SEQ ID NOs: 1 and 2.

Then, the recombinant vector of the present invention can be prepared by inserting a fragment of the resultant cDNA into known cloning vectors. Ligation of the cDNA fragments and the vectors may be accomplished by, for example, the above-mentioned method of Sambrook et al. Preferable vectors include a plasmid and a .lambda.-phage for Escherichia coli as the host, and an applicable plasmid is, for example, one derived from pBR322. A preferable .lambda.-phase is .lambda. gt11.

Transfer of the thus prepared recombinant vectors into the host may be conducted through infection by .lambda.-phage as presented in the above-mentioned paper by Sambrook et al. For example, a transformed cells with the recombinant vector containing the above-mentioned cDNA are available by inoculating the recombinant .lambda. gt11 into Escherichia coli Y1090 at 37.degree. C.

Selection of a transformed cell may be accomplished by using a known method, depending upon the kind of the cloning vector. For example, selection of a transformed cell with .lambda. gt11 can be performed as follows. The above-mentioned recombinant .lambda. gt11 containing the cDNA can be inoculated into Escherichia coli Y1090 under a temperature condition of 37.degree. C., and the E. coli cells are cultured on an ager plate containing trypton, yeast extract, NaCl and ampicillin (hereinafter abbreviated as an "agar medium"). Then, a nitrocellulose membrane containing isopropyl thio-D-galactoside (hereinafter abbreviated as "IPTG") is placed on the plate for another several hours to induce transcription from the integrated cDNA. After the binding of an enzyme-labelled CRK protein to the membrane (Matsuda et al., Mol. Cell. Biol., 12: 3482-3489, 1992), an lamda phase plaques having the recombinant vector can be selected by putting a substrate for the enzyme in it. A preferable labelling enzyme is alkaline phosphatase or peroxidase. CRK protein may be manufactured as a fusion protein with glutathione S-transferese (hereinafter abbreviated as "GST"), and selection may be accomplished by using an antibody against this GST.

The cDNA fragment inserted into .lambda. phage can be cleaved out and re-inserted into a plasmid vector, if necessary. An example or recombinant plasmid vector of the invention is pDOCK180 which is prepared by inserting the cDNA of SEQ ID NO: 1 into vector plasmid pBlue ScriptIIKS(+), for which details are presented in Example 2 later. The pDOCK180 was transfected into the XL1-Blue strain derived from Escherichia coli K12 strain, and the transformant E. coli DOCK180 having the pDOCK180 was deposited to National Institute of Biocience and human Technology, an international depository, under Budapest Treaty as a deposit No. FERM BP-5362 on Jan. 12, 1996.

Then, the DOCK180 protein of the present invention can be exressed from the cDNA of SEQ ID NO: 1. For production of the protein, an expression vector is prepared by inserting the cDNA fragment into a known expression vector. The cDNA fragment can be isolated from the above-mentioned cloning vector, pDOCK180. While there is no particular limitation as to the expression vector, a preferable one is pGEX1, pG5X2T or pGEX3X using E. coli as the host. The expression vector containing the cDNA fragment can be introduced into an Escherichia coli (for example, DH5 strain derived from Escherichia coli K12 strain) by a known method. The DOCK180 protein of the present invention is easily produced in a large scale by culturing the transformed cells. More specifically, a concrete example comprises the stops of culturing the transformed Escherichia coli at 37.degree. C. for 3 to 24 hours on L-broth containing ampicillin, bacteriolyzing through ultrasonic blending, and adsorbing this sample to a carrier such as glutathione sephalose (made by Pharmacia P-L Biochemicals Company), thereby isolating and purifying the target DOCK180 protein.

An antibody against DOCK180 protein is available by inoculating the thus purified DOCK180 protein to an animal by a conventional method. Applicable animals include rabbit, mouse, goat, sheep, horse and hamster, and among others, rabbit or mouse is preferable.

The thus obtained anti-DOCK180 protein antibody can be used, for example, for quantitative determination or separation of DOCK180 protein in a sample, and further, serves as a useful material for missile therapy using an antitumor agent with DOCK180 as a target.

The cDNA, the protein and the antibody of the present invention provide various genetic manipulation materials useful for development of a new cancer therapy. These materials include an antisense RNA of DOCK180 gene, a variant protein of DOCK180, and a virus vector which expresses these RNA, variant protein, and anti-DOCK180 protein antibody in tumor cells.

The present invention will be described below in further detail by means of examples. It is needless to mention that the present invention Is not limited in any manner by the following examples.

EXAMPLE 1

A cDNA fragment to human DOCK180 protein gene was isolated and cloned as follows.

An mRNA of DOCK180 gene was isolated from human spleen and a cDNA fragment was synthesized from the mRNA. The cDNA fragment was then integrated into .lambda. gt11, and a recombinant vector thereof was infected to Escherichia coli Y1090, which was plated onto LA agar culture medium. After six hours, a nitrocellulose membrane containing 1 mM IPTG was placed on this medium, and after three hours of culture, this nitrocellulose membrane was Incubated for an hour with a phosphate buffer solution (pH: 7.5) containing 2% skim milk and 0.05% Tween 20. Then, after reaction for an hour with a phosphate buffer solution containing 1 .mu.g/ml GST-CRK and 1 .mu.g/ml anti-GST monoclonal antibody, and for an hour with 1 .mu.g/ml alkaline phosphate-labelled anti-mouse antibody (made by TAGO Company), the phage having an ability to bind to CRK protein was identified by means of AP PURPLE (made by Bio Iol Company), a substrate for alkaline phosphatase. This phage was purified through three runs of plaque formation, and then DNA thereof was isolated by the phenol extraction method, and cleaved with a restriction enzyme EcoRI. Next, part of cDNA of DOCK180 gene was prepared through electrophoresis. This cDNA fragment was isotope-labelled with random oligo primer (made by Behlinger Company) and 32P-deoxycytidine triphosphate. With the use of this labelled cDNA, the above-mentioned recombinant .lambda. gt11 with cDNA derived from a human spleen was screened through plaque hybridization by the method of Sambrook et al. (Molecular Cloning, second edition, Cold Spring Harbor Laboratory, New York, 1989), and further six clones of recombinant .lambda. gt11 having DOCK180 protein cDNA were obtained. DNAs of these phages were cleaced with restriction enzyme EcoRI to isolate cDNA of DOCK180 gene and subcloned into phagemid vector pUC119. A single stranded DNA was purified from the thus obtained recombinant vector, and the nucleotide sequence thereof was determined by the use of an automatic nucleotide sequence reader (made by ABI Company). The identified nucleotide sequence thereof is shown in Sequence Listing by SEQ ID NO; 1, and the amino acid sequence of the anticipated translation product, by SEQ ID NO: 2. As a result of retrieval of this amino acid sequence in the database in the GenBank of the European Molecular Biology Laboratories (EMBL), the amino terminal end of DOCK180 protein shares homology with Fyn and Yes of tyrosine kinase by more than 20%. This domain has a structure known as SH3, and is present in various protein groups involved in signal transduction of cell proliferation in addition to that of tyrosine kinase. However, DOCK180 protein was found to be different from any known proteins and to be a new signal transduction factor.

EXAMPLE 2

From the group of recombinant pUC119 obtained in Example 1, the DNA fragments excluding overlapping portions were isolated and ligated each other to prepare a fragment containing all the translation domain of the cDNA. The resultant cDNA fragment was then inserted into the plasmid vector pBlue Script II KS(+) to obtain the recombinant vector pDOCK180. This pDOCK180 has a constitution as shown In FIG. 1.

Further, this cloning vector pDOCK180 was introduced into an XL1-Blue strain derived from Escherichia coli K12 to obtain a transformant E. coli DOCK180 (FERM BP-5362).

EXAMPLE 3

The cloning vector pDOCK180 obtained by Example 2 was cleaved with a restriction enzyme to prepare a cDNA domain of DOCK180 protein. The resultant cDNA fragment was then inserted into plasmid pGEX1, thereby preparing expression vectors. Transformant cells were prepared by introducing the expression vectors into Escherichia coli DH5. After culturing this transformant cells in 1 l L-broth containing ampicillin up to an absorbance of 0.6, IPTG was added to 0.5 mM, and culturing was continued for another three hours. After collection, the bacteria were ultrasonic-treated to remove crushed pieces of bacteria, and the supernatant was mixed with glutathione sephalose (made by Pharmacia P-L Biochemicals Company). After rinsing glutathione sephalose with a phosphate buffer solution, DOCK180 protein was eluded with the use of a phosphate buffer solution containing 5 mM glutathione. This protein was dialyzed with a phosphate buffer solution, and then a portion thereof was analyzed with SDS-polyacrylamide gel: a GST fused-DOCK180 protein having a purity of over 90% was synthesized.

EXAMPLE 4

The DOCK180 protein purified in Example 3 was subcutaneously inoculated three times to a rabbit, together with complete Freund's adjuvant, and then, serum was sampled.

Reactivity of this serum with the purified DOCK180 protein was investigated by the Western blotting technique: a clear reactivity was demonstrated with the DOCK180 protein even when diluted to about 1,000. This permitted confirmation of applicability thereof as an antibody against DOCK180 protein.

  __________________________________________________________________________
     SEQUENCE LISTING                                                          
     (1) GENERAL INFORMATION:                                                  
     (iii) NUMBER OF SEQUENCES: 2                                              
     (2) INFORMATION FOR SEQ ID NO:1:                                          
     (i) SEQUENCE CHARACTERISTICS:                                             
     (A) LENGTH: 6519 base pairs                                               
     (B) TYPE: nucleic acid                                                    
     (C) STRANDEDNESS: single                                                  
     (D) TOPOLOGY: linear                                                      
     (ii) MOLECULE TYPE: cDNA to mRNA                                          
     (iii) HYPOTHETICAL:                                                       
     (iv) ANTI-SENSE:                                                          
     (v) FRAGMENT TYPE:                                                        
     (vi) ORIGINAL SOURCE: spleen cell of homo sapiens                         
     (ix) FEATURE:                                                             
     (A) NAME/KEY: CDS                                                         
     (B) LOCATION: 24..5619                                                    
     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:                                   
     GCACGAGCGGCTCCGGCGGCGCCATGACGCGCTGGGTGCCCACCAAGCGCGAGGAGAAGT60            
     ACGGCGTGGCTTTTTATAACTATGATGCCAGAGGAGCGGATGAACTTTCTTTACAGATCG120           
     GAGACACTGTGCACATCTTAGAAACATATGAAGGGTGGTACCGAGGTTACACGTTACGAA180           
     AAAAGTCTAAGAAGGGTATATTTCCTGCTTCATATATTCATCTTAAAGAAGCGATAGTTG240           
     AAGGAAAAGGGCAACATGAAACAGTCATCCCGGGTGACCTCCCCCTCATCCAGGAAGTCA300           
     CCACGACACTCCGAGAGTGGTCCACCATCTGGAGGCAGCTCTACGTGCAAGATAACAGGG360           
     AGATGTTTCGAAGTGTGCGGCACATGATCTATGACCTTATTGAATGGCGATCACAAATTC420           
     TTTCTGGAACTCTGCCTCAGGATGAACTCAAAGAACTGAAGAAGAAGGTCACAGCCAAAA480           
     TTGATTATGGAAACAGAATTCTAGATTTGGACCTGGTGGTTAGAGATGAAGATGGGAATA540           
     TTTTGGATCCAGAATTAACTAGCACGATTAGTCTCTTCAGAGCTCATGAAATAGCTTCTA600           
     AACAAGTGGAGGAAAGGTTACAAGAGGAAAAATCTCAAAAGCAGAACATAGATATTAACA660           
     GACAAGCCAAGTTTGCTGCAACCCCTTCTCTGGCCTTGTTTGTGAACCTCAAAAATGTGG720           
     TTTGTAAAATAGGAGAAGATGCTGAAGTCCTCATGTCTCTATATGACCCTGTGGAGTCCA780           
     AATTCATCAGTGAGAACTACCTGGTTCGCTGGTCCAGTTCAGGATTACCTAAAGACATAG840           
     ACAGATTACATAATTTGCGAGCCGTGTTTACTGACCTCGGAAGCAAAGACCTGAAAAGGG900           
     AGAAAATCAGTTTTGTCTGTCAGATTGTTCGCGTGGGTCGCATGGAGCTGAGGGACAACA960           
     ACACCAGGAAACTGACCTCGGGGTTGCGGCGACCTTTTGGAGTGGCTGTGATGGATGTAA1020          
     CAGATATAATAAATGGAAAAGTAGATGATGAAGATAAGCAGCATTTCATTCCCTTTCAGC1080          
     CGGTGGCAGGGGAGAATGACTTCCTTCAGACTGTTATAAACAAAGTCATCGCTGCCAAAG1140          
     AAGTCAACCACAAGGGGCAGGGTTTGTGGGTAACATTGAAATTACTTCCTGGAGATATCC1200          
     ATCAGATCCGAAAAGAGTTTCCGCATTTAGTGGACAGGACCACAGCTGTGGCTCGAAAAA1260          
     CAGGGTTTCCGGAGATAATCATGCCTGGTGATGTTCGAAATGATATCTATGTAACATTAG1320          
     TTCAAGGAGATTTTGATAAAGGAAGCAAAACAACAGCGAAGAACGTGGAGGTCACGGTGT1380          
     CTGTGTACGATGAGGATGGGAAACGATTAGAGCATGTGATTTTCCCGGGTGCTGGTGATG1440          
     AAGCGATTTCAGAGTACAAATCTGTGATTTACTACCAAGTAAAGCAGCCACGCTGGTTTG1500          
     AGACTGTTAAGGTGGCCATTCCCATCGAGGACGTTAACCGCAGTCACCTTCGGTTTACCT1560          
     TCCGCCACAGGTCATCACAGGACTCTAAGGATAAATCTGAGAAAATATTTGCACTAGCAT1620          
     TTGTCAAGCTGATGAGATACGATGGTACCACCCTGCGAGACGGAGAGCACGATCTTATCG1680          
     TCTATAAGGCCGAAGCGAAGAAGCTGGAAGATGCTGCCACGTACTTGAGTCTGCCCTCCA1740          
     CGAAGGCAGAGTTGGAAGAAAAGGGCCACTCGGCCACCGGCAAGAGCATGCAGAGCCTTG1800          
     GGAGCTGCACCATTAGCAAGGACTCCTTCCAGATCTCCACGCTCGTGTGCTCCACCAAAC1860          
     TGACTCAGAACGTGGACCTTCTGGGGCTCTTGAAATGGCGCTCCAACACCAGCCTGCTGC1920          
     AGCAGAACTTGAGGCAGCTGATGAAAGTCGATGGTGGTGAAGTAGTGAAGTTTCTTCAGG1980          
     ACACGTTGGATGCCCTCTTCAACATCATGATGGAGAACTCAGAGAGTGAGACTTTTGACA2040          
     CGTTAGTCTTTGATGCTCTGGTATTTATCATTGGACTGATTGCTGATAGAAAATTTCAGC2100          
     ATTTTAATCCTGTTTTGGAAACTTACATTAAGAAACACTTTAGTGCAACGTTAGCCTACA2160          
     CGAAGTTGACAAAAGTGTTGAAGAACTACGTGGACGGTGCTGAGAAGCCGGGAGTAAATG2220          
     AGCAGCTGTACAAAGCCATGAAAGCGCTAGAATCCATCTTCAAGTTCATCGTGCGCTCCA2280          
     GGATCCTGTTCAATCAACTGTATGAAAACAAGGGAGAGGCTGACTTCGTGGAATCTTTGC2340          
     TGCAGCTCTTCAGGTCCATCAATGACATGATGAGCAGCATGTCAGACCAGACCGTCCGGG2400          
     TGAAGGGGGCAGCACTGAAATACTTACCAACGATCGTCAACGATGTGAAATTGGTGTTTG2460          
     ATCCCAAAGAGCTCAGCAAAATGTTTACTGAATTCATCCTCAATGTTCCCATGGGCTTGC2520          
     TGACCATCCAGAAACTCTACTGCTTGATCGAAATCGTCCACAGTGACCTCTTCACACAGC2580          
     ATGACTGCAGAGAGATCCTGCTTCCCATGATGACCGATCAGCTCAAGTACCATCTGGAGA2640          
     GACAGGAGGACCTGGAGGCCTGCTGTCAGCTGCTCAGCCACATCCTGGAGGTGCTGTACA2700          
     GGAAGGACGTGGGGCCAACCCAGAGGCACGTCCAGATTATCATGGAGAAACTTCTCCGGA2760          
     CCGTGAACCGAACCGTCATTTCCATGGGACGAGATTCTGAACTCATTGGAAACTTCGTGG2820          
     CTTGCATGACAGCTATTTTACGACAAATGGAAGATTACCATTATGCCCACTTGATCAAGA2880          
     CTTTTGGGAAAATGAGGACTGATGTGGTAGATTTCCTAATGGAAACATTCATCATGTTTA2940          
     AGAACCTCATTGGAAAGAACGTTTACCCCTTCGACTGGGTGATCATGAACATGGTGCAAA3000          
     ATAAAGTCTTCCTGCGAGCAATTAATCAGTATGCAGATATGCTGAACAAAAAATTTCTGG3060          
     ATCAAGCCAACTTTGAGCTACAGCTGTGGAACAACTACTTTCACCTGGCTGTTGCTTTCC3120          
     TTACTCAAGAGTCCCTGCAACTGGAGAATTTTTCAAGTGCCAAGAGAGCCAAAATCCTTA3180          
     ACAAGTACGGAGATATGAGGAGACAGATTGGCTTTGAAATCAGAGACATGTGGTACAACC3240          
     TTGGTCAACACAAGATAAAGTTCATTCCAGAAATGGTGGGCCCAATATTAGAAATGACAT3300          
     TAATTCCCGAGACGGAGCTGCGCAAAGCCACCATCCCCATCTTCTTTGATATGATGCAGT3360          
     GTGAATTCCATTCGACCCGAAGCTTCCAAATGTTTGAAAATGAGATCATCACCAAGCTGG3420          
     ATCATGAAGTCGAAGGAGGCAGAGGAGACGAACAGTACAAAGTGTTATTTGATAAAATCC3480          
     TTCTGGAACACTGCAGGAAGCACAAATACCTCGCCAAAACAGGAGAAACTTTTGTAAAAC3540          
     TCGTTGTGCGCTTAATGGAAAGGCTTTTGGATTATAGAACCATCATGCACGACGAGAACA3600          
     AAGAAAACCGCATGAGCTGCACCGTCAATGTGCTGAATTTCTACAAAGAAATTGAAAGAG3660          
     AAGAAATGTATATAAGGTATTTGTACAAGCTCTGTGACCTGCACAAGGAGTGTGATAACT3720          
     ACACCGAAGCGGCTTACACCTTGCTTCTCCATGCAAAGCTTCTTAAGTGGTCGGAGGATG3780          
     TGTGTGTGGCCCACCTCACCCAGCGGGACGGGTACCAGGCCACCACGCAGGGACAGCTGA3840          
     AGGAGCAGCTCTACCAGGAAATCATCCACTACTTCGACAAAGGCAAGATGTGGGAGGAGG3900          
     CCATTGCCTTGGGCAAGGAGCTAGCCGAGCAGTATGAGAACGAAATGTTTGATTATGAGC3960          
     AACTCAGCGAATTGCTGAAAAAACAGGCTCAGTTTTATGAAAACATCGTCAAAGTGATCA4020          
     GGCCCAAGCCTGACTATTTTGCTGTTGGCTACTACGGACAAGGGTTCCCCACATTCCTGC4080          
     GGGGAAAAGTTTTCATTTACCGAGGGAAAGAGTATGAGCCCCGGGAAGATTTTGAGGCTC4140          
     GGCTCTTAACTCAGTTTCCAAACGCCGAGAAAATGAAGACAACATCTCCACCAGGCGACG4200          
     ATATTAAAAACTCTCCTGGCCAGTATATTCAGTGCTTCACAGTGAAGCCCAAACTCGATC4260          
     TGCCTCCTAAGTTTCACAGGCCAGTGTCAGAGCAGATTGTAAGTTTTTACAGGGTGAACG4320          
     AGGTCCAGCGATTTGAATATTCTCGGCCAATCCGGAAGGGAGAGAAAAACCCAGACAATG4380          
     AATTTGCGAATATGTGGATCGAGAGAACCATATATACAACTGCATATAAATTACCTGGAA4440          
     TTTTAAGGTGGTTTGAGGTCAAGTCTGTTTTCATGGTGGAAATCAGCCCCCTGGAGAATG4500          
     CCATCGAGACCATGCAGCTGACGAACGACAAGATCAACAGCATGGTGCAGCAGCACCTGG4560          
     ATGACCCCAGCCTGCCCATCAACCCGCTCTCCATGCTCCTGAACGGCATCGTGGACCCAG4620          
     CTGTCATGGGGGGCTTCGCAAACTACGAAAAGGCCTTCTTTACAGACCGGTACCTGCAGG4680          
     AGCACCCTGAGGCCCATGAAAAGATCGAGAAGCTCAAGGACCTGATTGCTTGGCAGATTC4740          
     CTTTTCTGGCCGAAGGGATCAGAATCCATGGAGACAAAGTCACGGAGGCACTGAGGCCGT4800          
     TCCACGAGAGGATGGAGGCCTGTTTCAAACAGCTGAAGGAAAAGGTGGAGAAAGAGTACG4860          
     GCGTCCGAATCATGCCCTCAAGTCTGGATGATAGAAGAGGCAGCCGCCCCCGGTCCATGG4920          
     TGCGGTCCTTCACGATGCCTTCCTCATCCCGCCCTCTGTCTGTGGCCTCTGTCTCTTCCC4980          
     TCTCATCGGACAGCACCCCCTCCAGACCAGGCTCCGACGGGTTTGCCCTGGAGCCTCTCC5040          
     TGCCAAAGAAAATGCACTCCAGGTCCCAGGACAAGCTGGACAAGGATGACCTGGAGAAGG5100          
     AGAAGAAGGACAAGAAGAAGGAAAAAAGGAACAGCAAACATCAAGAGATATTTGAGAAAG5160          
     AATTTAAACCCACCGACATTTCCCTGCAGCAGTCTGAGGCTGTGATCCTTTCGGAAACGA5220          
     TAAGTCCCCTGCGGCCCCAGAGACCGAAGAGCCAGGTGATGAACGTCATTGGAAGCGAAA5280          
     GGCGCTTCTCGGTGTCCCCCTCGTCACCGTCCTCCCAGCAAACACCCCCTCCAGTTACAC5340          
     CAAGAGCCAAGCTCAGCTTCAGCATGCAGTCGAGCTTGGAGCTGAACGGCATGACGGGGG5400          
     CGGACGTGGCCGATGTCCCACCCCCTCTGCCTCTCAAAGGCAGCGTGGCAGATTACGGGA5460          
     ATTTGATGGAAAACCAGGACTTGCTGGGCTCGCCAACACCTCCACCTCCCCCTCCACACC5520          
     AGAGGCATCTGCCACCTCCACTGCCCAGCAAAACTCCGCCTCCTCCCCCTCCAAAGACAA5580          
     CTCGCAAGCAGACATCGGTGGACTCTGGGATCGTGCAGTGACATCGCAAGGCTCTCTGGA5640          
     AAGAGTGTGCTGCCCCTCCCCATCTCCATGCCCTCTCCTTCTGTGTCCCCTGAGTCTGCT5700          
     GTTTACCTCATTGGGCCTGTGATGTTAACATTTCGTGCGACTGCTTTTTCTTCAAAGGAG5760          
     TTCAGTTCTCACCATGGAGTGAGTGGCCTTTAGCGTCATGGAGCAAGGTGGGTCTGGGAG5820          
     GTAGATATGGGTCCGGGATGTGCCATCGTAGTTACCAGAGTTGGGGGCCTCTGAGTGTGT5880          
     CTGGCTCTGAGAGAGTCTGAGTCTTGCCCAAACATTCTTTCTTTTTGTGCCAAATGACTT5940          
     GCATTTGCAAAGAGCTCAATTGCTCTGAGCTCAGCCAAGTAGGAGAGGCTAGGCCATCAC6000          
     TCTTGGGAAGCTGTGTAGTGATGATGTATAAGAATCCTCCTCACTGTCATGGGATGTTGT6060          
     ATCCAGCCCCTCCTTGTTCCAGCCGGTGGTGTGACTTCGTTGGTTGAGGTGTGTCTCCAA6120          
     CCTACATCAGACCATGAAGTTCAACCCCTCCAGGGAAGCTCCTGATTTCCCCTGCATAAT6180          
     TGAAAATAGGATATTCTCAGCTATTGAACAGTTACTAATTTATGGGGTGGAAACAGCATT6240          
     AAGAATACTGAATCAAATGGAAAAACAAATGAATACAGGAAGATAAGTGTTCGTTCTTTT6300          
     CTGAAAAAAGAGTATGTGTACCACAAGAGCTGGTTTTAATTGGGTGAATTGTTTTTGTCC6360          
     TCATTCTGTACAGAAATTTGTATATATGATGGTTCTTAGAACTTGTTTTAATTTTTGTGG6420          
     TCCTTCTGTTTATTATAATAGGCGTCCACCAATGATTATCCATATGTGTTCTTAATTTTT6480          
     AACTGCTGGAAGTGTTAAAACACACACACCCCGGAATTC6519                               
     (2) INFORMATION FOR SEQ ID NO:2:                                          
     (i) SEQUENCE CHARACTERISTICS:                                             
     (A) LENGTH: 1865 amino acids                                              
     (B) TYPE: amino acid                                                      
     (C) STRANDEDNESS: single                                                  
     (D) TOPOLOGY: linear                                                      
     (ii) MOLECULE TYPE: protein                                               
     (iii) HYPOTHETICAL:                                                       
     (iv) ANTI-SENSE:                                                          
     (v) FRAGMENT TYPE:                                                        
     (vi) ORIGINAL SOURCE: spleen cell of homo sapiens                         
     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:                                   
     MetThrArgTrpValProThrLysArgGluGluLysTyrGlyValAla                          
     51015                                                                     
     PheTyrAsnTyrAspAlaArgGlyAlaAspGluLeuSerLeuGlnIle                          
     202530                                                                    
     GlyAspThrValHisIleLeuGluThrTyrGluGlyTrpTyrArgGly                          
     354045                                                                    
     TyrThrLeuArgLysLysSerLysLysGlyIlePheProAlaSerTyr                          
     505560                                                                    
     IleHisLeuLysGluAlaIleValGluGlyLysGlyGlnHisGluThr                          
     65707580                                                                  
     ValIleProGlyAspLeuProLeuIleGlnGluValThrThrThrLeu                          
     859095                                                                    
     ArgGluTrpSerThrIleTrpArgGlnLeuTyrValGlnAspAsnArg                          
     100105110                                                                 
     GluMetPheArgSerValArgHisMetIleTyrAspLeuIleGluTrp                          
     115120125                                                                 
     ArgSerGlnIleLeuSerGlyThrLeuProGlnAspGluLeuLysGlu                          
     130135140                                                                 
     LeuLysLysLysValThrAlaLysIleAspTyrGlyAsnArgIleLeu                          
     145150155160                                                              
     AspLeuAspLeuValValArgAspGluAspGlyAsnIleLeuAspPro                          
     165170175                                                                 
     GluLeuThrSerThrIleSerLeuPheArgAlaHisGluIleAlaSer                          
     180185190                                                                 
     LysGlnValGluGluArgLeuGlnGluGluLysSerGlnLysGlnAsn                          
     195200205                                                                 
     IleAspIleAsnArgGlnAlaLysPheAlaAlaThrProSerLeuAla                          
     210215220                                                                 
     LeuPheValAsnLeuLysAsnValValCysLysIleGlyGluAspAla                          
     225230235240                                                              
     GluValLeuMetSerLeuTyrAspProValGluSerLysPheIleSer                          
     245250255                                                                 
     GluAsnTyrLeuValArgTrpSerSerSerGlyLeuProLysAspIle                          
     260265270                                                                 
     AspArgLeuHisAsnLeuArgAlaValPheThrAspLeuGlySerLys                          
     275280285                                                                 
     AspLeuLysArgGluLysIleSerPheValCysGlnIleValArgVal                          
     290295300                                                                 
     GlyArgMetGluLeuArgAspAsnAsnThrArgLysLeuThrSerGly                          
     305310315320                                                              
     LeuArgArgProPheGlyValAlaValMetAspValThrAspIleIle                          
     325330335                                                                 
     AsnGlyLysValAspAspGluAspLysGlnHisPheIleProPheGln                          
     340345350                                                                 
     ProValAlaGlyGluAsnAspPheLeuGlnThrValIleAsnLysVal                          
     355360365                                                                 
     IleAlaAlaLysGluValAsnHisLysGlyGlnGlyLeuTrpValThr                          
     370375380                                                                 
     LeuLysLeuLeuProGlyAspIleHisGlnIleArgLysGluPhePro                          
     385390395400                                                              
     HisLeuValAspArgThrThrAlaValAlaArgLysThrGlyPhePro                          
     405410415                                                                 
     GluIleIleMetProGlyAspValArgAsnAspIleTyrValThrLeu                          
     420425430                                                                 
     ValGlnGlyAspPheAspLysGlySerLysThrThrAlaLysAsnVal                          
     435440445                                                                 
     GluValThrValSerValTyrAspGluAspGlyLysArgLeuGluHis                          
     450455460                                                                 
     ValIlePheProGlyAlaGlyAspGluAlaIleSerGluTyrLysSer                          
     465470475480                                                              
     ValIleTyrTyrGlnValLysGlnProArgTrpPheGluThrValLys                          
     485490495                                                                 
     ValAlaIleProIleGluAspValAsnArgSerHisLeuArgPheThr                          
     500505510                                                                 
     PheArgHisArgSerSerGlnAspSerLysAspLysSerGluLysIle                          
     515520525                                                                 
     PheAlaLeuAlaPheValLysLeuMetArgTyrAspGlyThrThrLeu                          
     530535540                                                                 
     ArgAspGlyGluHisAspLeuIleValTyrLysAlaGluAlaLysLys                          
     545550555560                                                              
     LeuGluAspAlaAlaThrTyrLeuSerLeuProSerThrLysAlaGlu                          
     565570575                                                                 
     LeuGluGluLysGlyHisSerAlaThrGlyLysSerMetGlnSerLeu                          
     580585590                                                                 
     GlySerCysThrIleSerLysAspSerPheGlnIleSerThrLeuVal                          
     595600605                                                                 
     CysSerThrLysLeuThrGlnAsnValAspLeuLeuGlyLeuLeuLys                          
     610615620                                                                 
     TrpArgSerAsnThrSerLeuLeuGlnGlnAsnLeuArgGlnLeuMet                          
     625630635640                                                              
     LysValAspGlyGlyGluValValLysPheLeuGlnAspThrLeuAsp                          
     645650655                                                                 
     AlaLeuPheAsnIleMetMetGluAsnSerGluSerGluThrPheAsp                          
     660665670                                                                 
     ThrLeuValPheAspAlaLeuValPheIleIleGlyLeuIleAlaAsp                          
     675680685                                                                 
     ArgLysPheGlnHisPheAsnProValLeuGluThrTyrIleLysLys                          
     690695700                                                                 
     HisPheSerAlaThrLeuAlaTyrThrLysLeuThrLysValLeuLys                          
     705710715720                                                              
     AsnTyrValAspGlyAlaGluLysProGlyValAsnGluGlnLeuTyr                          
     725730735                                                                 
     LysAlaMetLysAlaLeuGluSerIlePheLysPheIleValArgSer                          
     740745750                                                                 
     ArgIleLeuPheAsnGlnLeuTyrGluAsnLysGlyGluAlaAspPhe                          
     755760765                                                                 
     ValGluSerLeuLeuGlnLeuPheArgSerIleAsnAspMetMetSer                          
     770775780                                                                 
     SerMetSerAspGlnThrValArgValLysGlyAlaAlaLeuLysTyr                          
     785790795800                                                              
     LeuProThrIleValAsnAspValLysLeuValPheAspProLysGlu                          
     805810815                                                                 
     LeuSerLysMetPheThrGluPheIleLeuAsnValProMetGlyLeu                          
     820825830                                                                 
     LeuThrIleGlnLysLeuTyrCysLeuIleGluIleValHisSerAsp                          
     835840845                                                                 
     LeuPheThrGlnHisAspCysArgGluIleLeuLeuProMetMetThr                          
     850855860                                                                 
     AspGlnLeuLysTyrHisLeuGluArgGlnGluAspLeuGluAlaCys                          
     865870875880                                                              
     CysGlnLeuLeuSerHisIleLeuGluValLeuTyrArgLysAspVal                          
     885890895                                                                 
     GlyProThrGlnArgHisValGlnIleIleMetGluLysLeuLeuArg                          
     900905910                                                                 
     ThrValAsnArgThrValIleSerMetGlyArgAspSerGluLeuIle                          
     915920925                                                                 
     GlyAsnPheValAlaCysMetThrAlaIleLeuArgGlnMetGluAsp                          
     930935940                                                                 
     TyrHisTyrAlaHisLeuIleLysThrPheGlyLysMetArgThrAsp                          
     945950955960                                                              
     ValValAspPheLeuMetGluThrPheIleMetPheLysAsnLeuIle                          
     965970975                                                                 
     GlyLysAsnValTyrProPheAspTrpValIleMetAsnMetValGln                          
     980985990                                                                 
     AsnLysValPheLeuArgAlaIleAsnGlnTyrAlaAspMetLeuAsn                          
     99510001005                                                               
     LysLysPheLeuAspGlnAlaAsnPheGluLeuGlnLeuTrpAsnAsn                          
     101010151020                                                              
     TyrPheHisLeuAlaValAlaPheLeuThrGlnGluSerLeuGlnLeu                          
     1025103010351040                                                          
     GluAsnPheSerSerAlaLysArgAlaLysIleLeuAsnLysTyrGly                          
     104510501055                                                              
     AspMetArgArgGlnIleGlyPheGluIleArgAspMetTrpTyrAsn                          
     106010651070                                                              
     LeuGlyGlnHisLysIleLysPheIleProGluMetValGlyProIle                          
     107510801085                                                              
     LeuGluMetThrLeuIleProGluThrGluLeuArgLysAlaThrIle                          
     109010951100                                                              
     ProIlePhePheAspMetMetGlnCysGluPheHisSerThrArgSer                          
     1105111011151120                                                          
     PheGlnMetPheGluAsnGluIleIleThrLysLeuAspHisGluVal                          
     112511301135                                                              
     GluGlyGlyArgGlyAspGluGlnTyrLysValLeuPheAspLysIle                          
     114011451150                                                              
     LeuLeuGluHisCysArgLysHisLysTyrLeuAlaLysThrGlyGlu                          
     115511601165                                                              
     ThrPheValLysLeuValValArgLeuMetGluArgLeuLeuAspTyr                          
     117011751180                                                              
     ArgThrIleMetHisAspGluAsnLysGluAsnArgMetSerCysThr                          
     1185119011951200                                                          
     ValAsnValLeuAsnPheTyrLysGluIleGluArgGluGluMetTyr                          
     120512101215                                                              
     IleArgTyrLeuTyrLysLeuCysAspLeuHisLysGluCysAspAsn                          
     122012251230                                                              
     TyrThrGluAlaAlaTyrThrLeuLeuLeuHisAlaLysLeuLeuLys                          
     123512401245                                                              
     TrpSerGluAspValCysValAlaHisLeuThrGlnArgAspGlyTyr                          
     125012551260                                                              
     GlnAlaThrThrGlnGlyGlnLeuLysGluGlnLeuTyrGlnGluIle                          
     1265127012751280                                                          
     IleHisTyrPheAspLysGlyLysMetTrpGluGluAlaIleAlaLeu                          
     128512901295                                                              
     GlyLysGluLeuAlaGluGlnTyrGluAsnGluMetPheAspTyrGlu                          
     130013051310                                                              
     GlnLeuSerGluLeuLeuLysLysGlnAlaGlnPheTyrGluAsnIle                          
     131513201325                                                              
     ValLysValIleArgProLysProAspTyrPheAlaValGlyTyrTyr                          
     133013351340                                                              
     GlyGlnGlyPheProThrPheLeuArgGlyLysValPheIleTyrArg                          
     1345135013551360                                                          
     GlyLysGluTyrGluProArgGluAspPheGluAlaArgLeuLeuThr                          
     136513701375                                                              
     GlnPheProAsnAlaGluLysMetLysThrThrSerProProGlyAsp                          
     138013851390                                                              
     AspIleLysAsnSerProGlyGlnTyrIleGlnCysPheThrValLys                          
     139514001405                                                              
     ProLysLeuAspLeuProProLysPheHisArgProValSerGluGln                          
     141014151420                                                              
     IleValSerPheTyrArgValAsnGluValGlnArgPheGluTyrSer                          
     1425143014351440                                                          
     ArgProIleArgLysGlyGluLysAsnProAspAsnGluPheAlaAsn                          
     144514501455                                                              
     MetTrpIleGluArgThrIleTyrThrThrAlaTyrLysLeuProGly                          
     146014651470                                                              
     IleLeuArgTrpPheGluValLysSerValPheMetValGluIleSer                          
     147514801485                                                              
     ProLeuGluAsnAlaIleGluThrMetGlnLeuThrAsnAspLysIle                          
     149014951500                                                              
     AsnSerMetValGlnGlnHisLeuAspAspProSerLeuProIleAsn                          
     1505151015151520                                                          
     ProLeuSerMetLeuLeuAsnGlyIleValAspProAlaValMetGly                          
     152515301535                                                              
     GlyPheAlaAsnTyrGluLysAlaPhePheThrAspArgTyrLeuGln                          
     154015451550                                                              
     GluHisProGluAlaHisGluLysIleGluLysLeuLysAspLeuIle                          
     155515601565                                                              
     AlaTrpGlnIleProPheLeuAlaGluGlyIleArgIleHisGlyAsp                          
     157015751580                                                              
     LysValThrGluAlaLeuArgProPheHisGluArgMetGluAlaCys                          
     1585159015951600                                                          
     PheLysGlnLeuLysGluLysValGluLysGluTyrGlyValArgIle                          
     160516101615                                                              
     MetProSerSerLeuAspAspArgArgGlySerArgProArgSerMet                          
     162016251630                                                              
     ValArgSerPheThrMetProSerSerSerArgProLeuSerValAla                          
     163516401645                                                              
     SerValSerSerLeuSerSerAspSerThrProSerArgProGlySer                          
     165016551660                                                              
     AspGlyPheAlaLeuGluProLeuLeuProLysLysMetHisSerArg                          
     1665167016751680                                                          
     SerGlnAspLysLeuAspLysAspAspLeuGluLysGluLysLysAsp                          
     168516901695                                                              
     LysLysLysGluLysArgAsnSerLysHisGlnGluIlePheGluLys                          
     170017051710                                                              
     GluPheLysProThrAspIleSerLeuGlnGlnSerGluAlaValIle                          
     171517201725                                                              
     LeuSerGluThrIleSerProLeuArgProGlnArgProLysSerGln                          
     173017351740                                                              
     ValMetAsnValIleGlySerGluArgArgPheSerValSerProSer                          
     1745175017551760                                                          
     SerProSerSerGlnGlnThrProProProValThrProArgAlaLys                          
     176517701775                                                              
     LeuSerPheSerMetGlnSerSerLeuGluLeuAsnGlyMetThrGly                          
     178017851790                                                              
     AlaAspValAlaAspValProProProLeuProLeuLysGlySerVal                          
     179518001805                                                              
     AlaAspTyrGlyAsnLeuMetGluAsnGlnAspLeuLeuGlySerPro                          
     181018151820                                                              
     ThrProProProProProProHisGlnArgHisLeuProProProLeu                          
     1825183018351840                                                          
     ProSerLysThrProProProProProProLysThrThrArgLysGln                          
     184518501855                                                              
     ThrSerValAspSerGlyIleValGln                                               
     18601865                                                                  
     __________________________________________________________________________

Claims

1. A cDNA of a DOCK180 gene which encodes a DOCK180 protein having the amino acid sequence according to SEQ ID NO: 2.

2. A cDNA of a DOCK180 gene, which has a nucleotide sequence according to SEQ ID No: 1. and whose translation product binds to proto-oncogene product CRK.

3. A recombinant vector containing the cDNA as claimed in claim 2.

4. Plasmid pDOCK180, which is inserted in E. coli DOCK180 (FERM BP-5362).

5. A purified DOCK180 protein having an amino acid sequence according to SEQ ID NO: 2.

6. A DOCK180 protein having an amino acid sequence according to SEQ ID NO: 2, which is expressed from the cDNA of the DOCK180 gene claimed in claim 2.